A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

Summary

HX008 is a humanized monoclonal antibody targeting PD-1 on the T cell surface, restores T cell activity, thus enhancing immune response, and has the potential to treat various types of tumors. In this study, the tolerance and safety of HX008 in patients with advanced solid tumors will be evaluated.

Timeline

Start

2019-09-05

Primary completion

2021-05-30

Completion

2021-12-30

Drugs

Indications